FIELD: medicinal chemistry.
SUBSTANCE: bifunctional compounds used as modulators of the estrogen receptor (target protein). In particular, the present invention relates to bifunctional compounds having the chemical structure ULM-L-PTM, which contain at one end a ligand that binds to E3 ubiquitin ligase, and at the other end a fragment that binds to the target protein so that the target protein is located in the immediate vicinity of the ubiquitin ligase, with the implementation of destruction and inhibition of the target protein. In the general formula ULM-L-PTM: ULM is the chemical structure (a), W is selected from the group consisting of CH2, CHR and C=O; each X is O; Z is O; G is H; Q1, Q2, Q3 and Q4 are independently N or C independently substituted with R or H; A is H or linear or branched C1-6 alkyl; n is 1, 2 or 3; each R is independently selected from -OR', -NR'R", -CR'R"-, 6-membered aryl, 5- or 6-membered heteroaryl with one or two heteroatoms, linear or branched C1-6alkyl, C3-7cycloalkyl, C3-7heterocyclyl with one, two or three heteroatoms, where one R is covalent-bonded to L; R' and R'' independently represent a bond or H; and is a bond that may or may not provide a stereospecific configuration; and where each ULM heteroatom is nitrogen; L is a chemical linker group represented by the formula -(AL)q-, wherein (AL)q is connected to ULM and PTM; q is 1, 2, 3 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13; each AL is independently selected from a bond, CRL1RL2, O, S, SO, SO 2, NRL3, CO, C≡C, C3-11cycloalkyl, C3-11heterocyclyl having 1 or 2 N or O atoms and optionally substituted with 1 RL1 group, and 5- or 6-membered heteroaryl having 1, 2 or 4 N atoms; and each of RL1, RL2, RL3, RL4 and RL5 independently represents H, halogen or C1-8alkyl; PTM is the structure of formula (IPTM), each XPTM is independently CH or N; indicates the place of attachment L; RPTM1 represents 1, 2 or 3 substitutions, each substitution is independently selected from OH, halogen and C1-6alkoxy; RPTM2 represents 1 or 2 substitutions, each substitution is independently selected from H, halogen, CF3, linear or branched C1-6alkyl, methoxy; RPTM3 is 1 or 2 substitutions, each substitution is independently H or halogen; and RPTM4 is H or methyl.
EFFECT: modulators of the estrogen receptor (target protein).
13 cl, 7 dwg, 544 ex
Title | Year | Author | Number |
---|---|---|---|
ESTROGEN RECEPTOR PROTEOLYSIS MODULATORS AND RELATED USES THEREOF | 2018 |
|
RU2797808C2 |
PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
COMPOUNDS TARGETING TAU PROTEIN AND RELATED USE THEREOF | 2017 |
|
RU2805523C2 |
COMPOUNDS TARGETING BRM AND RELATED USES THEREOF | 2019 |
|
RU2797832C2 |
CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM | 2018 |
|
RU2795146C2 |
BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773346C2 |
COMPOUNDS FOR TREATING COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2703995C2 |
MEK INHIBITORS AND THEIR THERAPEUTIC USE | 2021 |
|
RU2812929C1 |
MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | 2014 |
|
RU2665709C2 |
Authors
Dates
2023-06-01—Published
2017-12-01—Filed